홈 카테고리 맞춤형시장조사 국제컨퍼런스 글로벌 파트너 메일링 서비스 회사소개회사소개 Contact Us
English Japaness Chinese
Home > 시장보고서 > 파머슈티컬 > 제네릭 의약품 > Pricing and Reimbursement Issues for Generics & Biosimilars Markets in Europe
카테고리
파머슈티컬 (4931)
감염질환 (349)
골질환 치료 (38)
당뇨병 (194)
백신 (181)
비만치료/다이어트 (44)
비처방 의약품 (152)
수의학 (17)
신경질환 (174)
신약개발 (1529)
암치료 (941)
약물전달 (185)
의약품 규제환경 (127)
정신질환 (86)
제네릭 의약품 (128)
제약회사분석 (523)
처방약 (165)
시장보고서

Pricing and Reimbursement Issues for Generics & Biosimilars Markets in Europe

리서치사 Frost & Sullivan
발행일 2006년 12월 상품코드 48391
페이지 정보 51 Pages
가격
US $ 6,500 ￦ 7,744,700 Web Access (Regional License)
US $ 7,000 ￦ 8,340,500 Hard Copy & Web Access (Regional License)


영문목차

Abstract

This Frost & Sullivan research service titled Pricing and Reimbursement Issues for Generics & Biosimilars Markets in Europe provides a detailed analysis of various issues affecting pricing and reimbursement decisions of generics in Europe. The study includes an overview of cost-containment measures such as reference pricing, parallel trade, generic substitution, patient co-payments and reimbursement. Certain key issues such as the EU accession, the Roche/Bolar provision, data exclusivity and marketing authorisation applications are also discussed.

Table of Contents

1. Executive Summary

  • 1. Executive Summary
    • 1. Executive Summary

2. Glossary of Terms

  • 1. Important Terms
    • 1. Definitions

3. Research Methodology

  • 1. Methodology Of Research
    • 1. The "12 Step" Market Engineering Research Methodology and Process

4. Introduction

  • 1. Overview
    • 1. Market Analysis
    • 2. Scope and Objectives
    • 3. Pricing and Reimbursement
    • 4. The Biosimilars Opportunity

5. Key Trends

  • 1. Pharmaceutical Cost-containment Measures
    • 1. Reference Pricing
    • 2. Parallel Trade
    • 3. Generic Substitution
    • 4. Patient Co-payments and Reimbursement
  • 2. Political/Legal/Regulatory Issues
    • 1. Impact of EU Accession
    • 2. The Roche/Bolar Provision
    • 3. Data Exclusivity and Marketing Authorisation Applications

6. Country-wise Policy Analysis

  • 1. Group I
    • 1. Denmark
    • 2. Germany
    • 3. The Netherlands
    • 4. The United Kingdom
  • 2. Group II
    • 1. Austria
    • 2. Belgium
    • 3. France
    • 4. Italy
    • 5. Portugal
    • 6. Spain
  • 3. Group III
    • 1. Central and Eastern Europe (CEE)

7. Market Participants

  • 1. Market Players
    • 1. List of Generics Market Participants
    • 2. List of Biosimilars Market Participants

8. Strategic Recommendations

  • 1. Recommendations to Market Participants
    • 1. Strategic Suggestions

9. Decision Support Databases

  • 1. DSDs
    • 1. Total Healthcare Expenditure
    • 2. Pharma R&D Expenditure

List of Figures

Chapter 4

  • Generics Market: Market Share of Generics by Value and Volume (Europe), 2004

Chapter 5

  • Generics Market: Country-wise Policy on Generic Substitution (Europe), 2006
  • Generics Market: Average Time Required for Pricing and Reimbursement Approvals (Europe), 2004

Chapter 7

  • Generics Market: List of Key Market Participants (Europe), 2006
  • Biosimilars Market: List of Key Market Participants (Europe), 2006
Back to Top